Enteritis F9: Enteritis with superfical gastritis, diarrhea, low energy or digestive tract reactions due to radiation therapy.
1. Enteritis: 84 chronic enteritis patients were treated with F9 for up to a month and 57 cured (67.85 percent), 14 significantly improved (16.66 percent), 10 improved (11.90 percent) and three did not improve (3.57 percent).
2. Superfical gastritis: 32 superfical gastritis patients took F9 and 15 cured (46.8 percent), 9 significantly improved (28.1 percent), 7 improved (21.8 percent) and one did not.
3. Digestive tract dysfunction: 84 patients were divided into a treatment group (n=57) taking F9 and a comparison group (n=27) taking regular medication. There was a significant difference in the cure rate: 86 vs. 16 percent, P<0.01.
4. Urinary tract stone: 21 patients who had been treated for more than two months with few effect took F9 or its modification for a month and 18 cured (85 percent) while the other three did not improve.
5. Digestive tract reaction due to radiation therapy: 96 patients took F9 to correct the digestive tract reaction due to chemo therapy. 33 cured (34.4 percent), 46 improved (47.9 percent) and 17 did not respond (17.7 percent). Other 35 patients were divided into a treatment group taking F9 and a comparison group taking regular medicine for three weeks. There is a very significant difference in the cure rate: 85 vs. 13 percent, P<0.01.
6. Diarrhea: 95 unknown reason diarrhea patients took F9 or other formulas found 27 significantly improved (28.42 percent), 41 improved (43.15 percent) and 27 did not improve (28.42 percent). Pediatric diarrhea: 42 children have been treated with F9 and all were cured.
7. Pompholyx: 48 patients took F9 for an average of a week and 42 cured (87.5 percent) and 6 significantly improved (12.5 percent).
Toxicity and side effects: There is no toxicity report or known side effect of F9.
